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Tuberculosis (TB) is a curable and preventable disease; however, in 2015, 10.4 million 
people were diagnosed with TB, making it one of the top 10 causes of mortality. A major 
part of the TB disease burden is carried by low and middle-income countries. In Ethiopia, 
which ranks 15th among 22 countries with a high burden of TB and multidrug resistant 
TB (MDR-TB), important diagnostic and treatment gaps persist. This quantitative 
descriptive study was primarily aimed to determine levels of adherence to standardized 
TB laboratory procedures by calculating and reporting the number of sputum samples, 
and reporting valid and documented results of laboratory Ziehl Neelsen (ZN) stain tests 
and MDR-TB tests for each suspected TB patient at a community health center TB 
laboratory in Addis Ababa, Ethiopia. The social theory of unanticipated consequences for 
purposive or social action was the theoretical framework for this study. Study results 
revealed that the optimal number of 3 samples sputum specimens collected for each 
suspected TB patient was submitted only for 48.1% of the study population. Also, 
regarding the percentage of valid and documented results for the 3 samples when 
performing laboratory ZN stain tests, for each suspected TB patient, there were valid 
results only for 72.2%, 51.2%, and 47.5% of the study participants, respectively. Finally, 
the percentage of valid and documented results when performing the MDR-TB test for 
each suspected TB patient was only 13.6%. For all the data, WHO criteria for 
error/undocumented results were not met. The study will contribute to changing the way 
Ethiopian laboratory technicians and managers address local challenges involving TB 
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Section 1: Foundation of the Study and Literature Review  
Introduction 
The genus Mycobacterium originated more than 150 million years ago .  The 
organism Mycobacterium tuberculosis causes tuberculosis (TB). TB is a communicable 
disease (World Health Organization [WHO], 2019). The disease is spread from person to 
person through the air; when people with lung TB cough, sneeze, or spit, they propel the 
TB germs into the air. A person needs to inhale only a few of these germs to become 
infected. People infected with TB bacteria have a 5-15% lifetime risk of falling ill with 
TB. However, persons with compromised immune systems, such as people living with 
HIV, malnutrition, or diabetes, or people who use tobacco, have a much higher risk of 
falling ill (WHO, 2018). Undiagnosed and thus untreated Mycobacterium tuberculosis 
infection is deadly and if undiagnosed and untreated it leaves the country’s population 
vulnerable to spreading the bacteria to families and to community members.   
TB disease is a curable and preventable disease; however, in 2015, 10.4 million 
people were diagnosed with TB, making it one of the top 10 causes of death, with a death 
toll of 1.4 million worldwide (WHO, 2017b). Even though many steps have been taken to 
eradicate the disease, in 2015, TB was still one of the top 10 killers globally, ranking 
above HIV/AIDS as a leading cause of death from infectious disease (WHO, 2016a).     
A major part of the TB disease burden is carried by low and middle-income 
countries (LMIC), as TB is a disease of the poor. Houben et al. (2016) said that the high 
burden of TB disease in LMICS requires even more accelerated TB prevention programs 




identification, diagnosis, and treatment with the hopeful result of saving lives. Detection 
of the organism is achieved through laboratory procedures that can be simple manual 
procedures or expensive and highly technical automated procedures.   
TB disease is a debilitating disease and treatment can only be initiated after 
detection of the organism causing the infection. Therefore, accurate and timely diagnosis 
followed by access to immediate treatment will save lives and resources. This can only be 
achieved through social change that empowers local level laboratory professionals and 
managers to own the process and initiate and sustain laboratory methodologies that 
consider local resources. 
The rise of multidrug-resistant TB (MDR-TB) and extensively-drug resistant TB 
(XDR-TB) infection have created more challenges for health professionals as they 
continue to eradicate infections. MDR-TB is TB infection that does not respond to at 
least isoniazid and rifampicin, the two most powerful anti-TB drugs (WHO, 2017c). 
XDR-TB is a form of MDR-TB with additional resistance to more anti-TB drugs that 
therefore responds to even fewer available medicines. It has been reported in 117 
countries worldwide (WHO, 2017c). 
MDR-TB and XDR-TB continue to emerge because of the mismanagement of TB 
treatment and person-to-person transmission of MDR-TB infections. Most people with 
TB are cured by strictly following a 6-month drug regimen, but inappropriate or incorrect 
use of antimicrobial drugs or use of ineffective formulations of drugs (such as single 
drugs, poor quality medicines, or unacceptable storage conditions), and premature 




especially in crowded settings such as prisons and hospitals (WHO, 2018). In some 
countries, it is becoming increasingly difficult to treat MDR-TB. Treatment options are 
limited and expensive. At $1000 U.S. dollars per patient, the new treatment regimen can 
be completed in 9-12 months and recommended medicines are not always available, and 
patients experience many adverse effects from the drugs.   
The WHO (2016a) reported that the equivalent of $6.6 billion U.S. dollars was 
available for TB prevention, diagnosis, and treatment in low- and middle-income 
countries in 2016. They based their determination on data reported to the WHO for 126 
countries with 97% of the world’s notified TB cases. This amount in 2016 was an 
increase from previous years, but was still about $2 billion U.S. dollars less than the 
estimated requirement for this group of countries. The Who (2016a) stressed the need for 
$2 billion U.S. dollars and more commitment from local and international agencies. 
    The target to end global TB is reflected in the WHO’s Sustainable Development 
Goals (SDG). The SDGs were adopted by the United Nations (UN) in September 2015 
and covers the period 2016 to 2030. The End TB Strategy has a 20-year timeframe 
(20162035) and was unanimously endorsed by the WHO’s member states at the 2014 
World Health Assembly. Targets set for the End TB Strategy included a 90% reduction in 
TB deaths and 80% reduction in TB incidence by 2030, as compared to 2015 (WHO, 
2016a). 
 Ethiopia is one of the world’s oldest civilizations and one of the world’s poorest 
countries (World Bank, 2017). It is the second-most populous country in Sub-Saharan 




Poverty and dense population lead to a higher rate of transmission of communicable 
diseases, including TB. Ethiopia ranks 15 among the 22 countries with a high burden of 
TB and MDR-TB. In Ethiopia, the annual HIV-negative TB mortality and HIV-positive 
TB mortality is estimated to be 15,000 to 38,000 deaths and 1,600 to 7,300 deaths, 
respectively. Globally, 22 countries are considered to have a high burden of TB and 
MDR-TB and Ethiopia ranks 15 among these countries. Table 1 shows estimated TB 
burden in Ethiopia. 
Table 1   
TB Disease Burden in Ethiopia 2014  





 Rate per 100,000 population 
Mortality (excludes HIV+TB) 32 (22-43) 33 (23-44) 
Mortality (HIV+TB only) 5.5 (4-4-6.8) 5.7 (4.6-7) 
Prevalence (includes HIV+TB) 190 (160-240)  200 (161-243) 
Incidence (includes HIV+TB) 200 (160-240) 207(168-250) 
Incidence (HIV+TB only) 19 (15-23) 19 (15-24) 
Case detection, all forms (%) 60 (49-73)  
 
 The Federal Ministry of Health (FMOH, 2015) reported that important 
diagnostic and treatment gaps persist and listed the irregular supply of laboratory reagents 
as one of the top challenges. From 2014 to 2015, the TB case detection rate (number of 




67.3%, which was below the 83.0% target set by the WHO for the same year.  Reves and 
Angelo (2016) noted that a major impediment to achieving the End TB Strategy in 
Ethiopia is the low TB case detection rate, which was 60% in 2015.  Reves and Angelo 
said that 25% of the estimated 2,200 MDR-TB patients were identified. Therefore, it is 
important to increase the detection rate of TB and MDR-TB in Ethiopia.  
 Reviewing laboratory procedures may provide a better understanding of the 
challenges public health officials face when seeking to improve TB and MDR-TB 
detection rates in Ethiopia. To aid in this endeavor, this doctoral study assessed daily TB 
laboratory procedures at Community Health Center TB Laboratory in Addis Ababa from 
August 1, 2015 to December 31, 2016.  
 In this section, the problem statement, purpose, research questions, theoretical 
framework, literature review regarding concepts under study, assumptions, definitions, 
and scope and delimitations will be discussed. 
 Problem Statement 
    There is a problem regarding delay and accurate diagnosis and treatment for TB 
patients.  Houben et al. (2016) said that the high burden of TB disease in LMICs requires 
even more accelerated TB diagnosis tools and prevention programs. Ethiopia is one of the 
high burden countries (HBCs), and it will be the focus of my proposed research. 
Improving the low TB case detection rate is a challenge that Ethiopia faces, as the 
country is moving to achieve End TB Strategy objectives by 2035.  The WHO (2016a) 




which is a much lower annual rate compared to the 4.5% yearly rate of decline needed by 
2020 to meet the 2030 TB objective.  
Another area of concern when considering how to enhance TB prevention is a 
delay in diagnosis. Although, there are regional variations for the delay in TB diagnosis 
and treatment, Bogale, et al. (2017) stated in Northwestern Ethiopia, it generally ranges 
from 40–97 days. Many factors cause a delay in diagnosis and treatment, but it is mainly 
related to health care seeking behavior, health system delivery, and timely diagnosis and 
treatment (Bogale et al. 2017).    
There are various procedures to diagnose TB. A direct sputum smear examination 
using Ziehl Neelsen (ZN) staining is the most commonly-used procedure in many low-
income counties, including Ethiopia. The method is low-priced, but its low sensitivity is a 
problem (Kivihya-Ndugga, van Cleeff, Juma, & Kimwomi, 2004). Depending on the 
number of specimens examined, ZN detects 30- 60% of culture-positive TB suspects. 
Moreover, a collection of sputum samples on three consecutive days is required, which is 
burdensome for patients and makes compliance difficult. Therefore, this might delay 
diagnosis and treatment. Polymerase chain reaction (PCR) techniques have higher 
sensitivity and specificity than conventional smear examination with ZN stain. However, 
the presence of a reliable support system that includes training and timely technical 
backing is highly recommended to make the PCR testing worthwhile.  Among culture-
positive patients, a single direct MTB/RIF test identified 551 of 561 patients with smear-
positive tuberculosis (98.2%) and 124 of 171 with smear-negative tuberculosis (72.5%). 




investigate that diagnostic tools are accurate, adhere to WHO standards, and are 
supported by available resources in the local area to have a direct impact on case 
prevention and saving lives. 
Purpose of the Study 
This quantitative descriptive study primarily aimed to determine levels of 
adherence to standardized TB laboratory procedures by calculating and reporting the 
number of sputum samples from each suspected TB patient, and the valid/documented 
results of laboratory ZN stain test and MDR-TB test for each suspected TB patient at a 
Community Health Center TB laboratory in Addis Ababa, Ethiopia. Second, I compared 
these data to similar data reported by the WHO and other countries to ascertain how 
Ethiopia stands regarding these standardized procedures.  
There are significant inequalities that exist among and between countries in terms 
of their ability to access TB diagnostic and treatment. Of the estimated 9.6 million people 
who fell ill with TB globally in 2014, 6 million (62.5%) were reported to national 
authorities (WHO, 2015). Worldwide, 37.5% of TB cases went undiagnosed or were not 
reported to local governments/health authorities, posing a high risk of transmission to 
communities. TB diagnosis and treatment is an essential part of any country’s health 
delivery system, and there are multiple factors contributing to delays in diagnosis and low 
case detection rates. The proposed research explored laboratory procedural capabilities 
and limitations in a community health center TB laboratory in Addis Ababa, a major 




     From 2015 to 2016, the laboratory at a community health center TB laboratory 
in Addis Ababa used the ZN acid-fast bacilli (AFB) stain procedure to determine the 
presence and absence of  tuberculosis bacteria in sputum samples. Also, the community 
health center used a Gene- Xpert PCR instrument to determine the presence and absence 
of MTB and to determine if the organism is resistant to rifampin. The device is endorsed 
for use in resource-limited settings. Rifampin is one of the first-line antibiotics used to 
treat TB infection; therefore, determining if TB organisms are resistant to rifampin 
enables clinicians to adjust medication and help TB infection control programs stop the 
spread of rifampin-resistant TB in the community. 
The ZN AFB stain procedure requires three sputum samples from patients 
suspected to have TB infection. There are several steps that the laboratory is required to 
follow to produce reliable laboratory results. The procedural steps that the Community 
Health Center TB laboratory in Addis Ababa use and the WHO laboratory manual will be 
described in detail.  Daily activities of the laboratory will be obtained from secondary 
data. Data will include the number of sputum samples collected, number of ZN stain 
performed, the number of ZN stain results documented, results of Gene Xpert PCR tests 
documented, and number of laboratory test results errors, invalid results, and no result 
documentation. The study analyzed any undocumented laboratory results, error codes, 
and invalid laboratory results as a measure of the level of the laboratory’s procedural 





RQ1: During the period between August 1, 2015 and December 31, 2016 at a 
community health center TB laboratory in Addis Ababa, what was the number of sputum 
samples for detection of mycobacterium tuberculosis for suspected TB patients?  
RQ2: Between August 1, 2015 and December 31, 2016 at a community health 
center TB laboratory in Addis Ababa, what was the percentage of valid/documented 
results when performing the laboratory ZN stain test for suspected TB patients?     
RQ3: During the period between August 1, 2015 and December 31, 2016 at a 
community health center TB laboratory in Addis Ababa, what was the percentage of 
valid/documented results when performing laboratory MDR-TB tests for suspected TB 
patients?  
Theoretical Foundation of the Study 
Global health issues involve unique social dynamics that set them apart from all 
other social phenomena. Kleinman (2010) stated that global health is often viewed as a 
collection of health problems rather than a science discipline. However, the social theory 
of unanticipated consequences for purposive (or social) action can help understand 
challenges Ethiopia is facing in fighting TB. Sociologist Robert Merton first introduced 
the theory in 1936. Merton (1936) said one acts rationally by selecting means based on 
the available evidence, and yet the health goal may not be attained. Unorganized action 
refers to acts of individuals, and the formally organized action refers to like-minded 
individuals who form an association to achieve a common purpose. Unanticipated 
consequences may follow both types of action. Merton was interested in consequence of 




 Limited knowledge can be the sole barrier to correctly anticipating a future 
outcome. Solinas-Saunders and Stacer (2015) said that some health interventions result in 
unintended consequences that are unpredictable while some are seen and prevented. One 
example is the unintended consequence of China’s one-child per family population 
control policy, which gave birth to a sexual revolution in China (Kleinman, 2010).   
 Merton’s theory of unintended consequences of social action is useful to 
investigate how decision-makers decide what is beneficial for a local area.  But Solinas-
Saunders and Stacer (2015) noted that many factors are intertwined and choices are 
formed within a social context constrained by time and space.  One’s action rationality is 
a function of their interpretation of reality in the context of a social system (Merton, 
1936). Rationality is not synonymous with objectivity.  Rationality is subjective since it 
is determined by human actions within the boundaries of an existing social structure 
(Solinas-Saunders & Stacer, 2015). Based on Merton’s theory of unintended consequence 
of purposive action, the demand for social engagement is pressing, as is the need for 
immediate results. 
According to Merton (1936), available knowledge is another way in which 
decision-makers’ conclusions are restrained.  When trying to decide what type of 
treatment, diagnostic procedures, or medical equipment is appropriate, decision-makers 
need information about local resources, culture, practices, needs, and wants of the local 
area.  Solinas-Saunders and Stacer (2015) said acquiring sufficient knowledge takes 
energy and time, that actors including local health professionals and international 




interest. Consequently, decision-makers are limited in their ability to anticipate 
consequences of purposive actions correctly. They lack knowledge or the ability to 
translate knowledge into empirical data with the need to obtain immediate results limits 
the ability to predict results with certainty (Merton, 1936). Therefore, the proposed study 
assessed day-to-day laboratory activities to understand challenges and limitations that 
were not apparent at the time of decision making. The issue of Ethiopia’s limited 
infrastructure, insufficient technical training, and limited troubleshooting abilities of 
laboratorians need to be considered in full before making any decisions. It is also crucial 
to investigate infrastructure capabilities, training, and technical support. These activities 
should be determined, sustained, and managed by the country’s local health department 
managers with total backing from decision-makers and international agencies. 
Nature of the Study 
The study encompassed descriptive quantitative analysis of secondary data from 
August 1, 2015 to December 31, 2016 obtained from a community health laboratory in 
Addis Ababa, Ethiopia. The variables under study are number of specimens collected, TB 
microscopic test results, and MDR-TB test results using the Gene Xpert instrument, as 
indicated in laboratory records. 
The WHO (2013) indicated that three consecutive sputum microscopies can 
identify 95- 98% smear-positive samples. The WHO (2013) said to collect the first 
specimen, early morning at home. The second sample should be collected when the 
patient presents to the laboratory on visit #1 and bring the third specimen the following 




specimens collected on the same day may be performed. The minimum expectation the 
WHO set for HBCs is 90%. Analysis of laboratory functions will determine what the 
laboratory currently is doing and should be doing based upon WHO recommendations. 
The study involved data obtained from a community h/ealth center using descriptive 
statistics to understand gaps and successes of the laboratory procedural steps.  Data 
analysis included data from the collection of three sputum specimens, results of sputum 
smear microscopic tests, and results of Gene Xpert PCR tests during August 1, 2015 to 
December 31, 2016. Secondary data for this study did not include patients’ treatment 
information. Therefore, the study did not examine associations between laboratory patient 
results and treatment success or failure. 
Literature Search and Strategy 
The literature review is central to the research study. A literature review provides 
the foundation for research by including those articles that highlight the importance of the 
research questions. After formulating research questions, researchers move to understand 
what studies have been done and conclusions have been reached involving the research 
questions. During the literature review, reviewers seek to synthesize published research 
findings that relate to the research questions. It is also essential that reviewers evaluate 
literature for applicability, thoroughness, and significance as they apply to research 
questions. A necessary part of the literature review includes health information data, and 
population surveys conducted by local or international organizations. 
I used CINAHL, MEDLINE, and Thoreau to access many full-text and peer-




Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), 
Tuberculosis Research Advisory Committee (TRAC), and the FMOH.  I reviewed annual 
reports and articles related to MTB infections, diagnosis, and treatment. Search terms 
used were: Mycobacterium tuberculosis, high burden countries, MTB diagnosis, TB in 
Ethiopia, TB laboratory in Addis Ababa, TB laboratory, GeneXpert instrument, MDR-TB 
and TB case detection rate, TB microscopic, laboratory procedures, and TB in Sub-
Sharan Africa. 
Literature and journals reviewed include articles published between 2009 and 
2017. The journal articles I reviewed addressed burdens of TB and TB diagnosis in 
Ethiopia extensively. Other topics of interest were poverty, access to healthcare, 
laboratory management, TB laboratory procedures in Ethiopia, and laboratory 
management systems in other LMICs. 
Literature Review 
Addis, Birhan, Derseh, Sahle, and Gizaw. (2013) said that a considerable 
contributor to the root cause of dissatisfaction for Ethiopian healthcare professionals is 
poor quality of laboratory support. Haile, Mesfin, McNerney, and Gezehegn. (2014) said 
a major challenge for Ethiopian laboratories is to get continued commitments from 
managers and administrators to maintain laboratory excellence. Shortage of reagents and 
other consumable materials, including quality control materials, and lack of adequate 
resources for training laboratory personnel is a countrywide problem in Ethiopia. 
Countries with limited resources do not need to adapt to recent technologies 




training, the ability to troubleshoot and correct instrument error messages, daily quality 
control and preventative maintenance of instruments, and ongoing competency 
verification. Sinishaw, Gebregorgis, and Shiferaw (2015) researched 82 health centers in 
the Amahara region in Ethiopia, and found that 40.2% of the health centers were 
understocked in terms of at least one reagent that is required to diagnose TB infection. 
Moreover, 93% of the 82 health centers did not fulfill the standard for effective 
distribution of laboratory supplies (Sinishaw et al., 2015). Reagents, supplies, and 
technical assistance are out of reach for some laboratories, which causes delays of test 
results or can produce incorrect results. Such delay defeats the purpose of engaging in the 
use of advanced technology. Ridderhof, Deun, Kam, Narayan, and Azize (2007) said that 
TB laboratories could either serve as a vehicle for progress or can inhibit further progress 
in TB control. 
About half of the medical equipment in developing countries are poorly 
maintained; therefore, they are often out of order (Fonjungoa et al. 2012). Manalebh, 
Demissie, Mekonnen, and Abera (2015) conducted a cross-sectional study to evaluate 
sputum smear microscopy in 37 public-private mix (PPM) laboratories in the Western 
Region, Ethiopia. Manalebh et al. (2015) employed onsite evaluation and blind 
rechecking, and 67.6% of PPM-DOTS laboratories were found to be below standard 
recommended physical space. The quality of AFB staining reagents were also found to be 
substandard in private DOTS laboratories.  These led to poor quality of sputum smear 
microscopy, and internal quality control was not regularly practiced. Sinishaw et al. 




Smear thickness and evenness were not acceptable in 66.2% and 62.7% of laboratories, 
respectively. The study also confirmed an inefficient supply distribution system which 
left many health centers with no or low stocks of TB reagents and supplies. Reagents and 
supplies are also central to quality assurance processes. Decentralized quality assurance 
processes improve TB microscopic test results. Melese et al. (2016) said external quality 
assurance (EQA) processes were expanded from four regional laboratories to 82 EQA 
centers, which included 956 health facilities (HFs). The EQA process involved 
rechecking AFB smears for false negatives (FN) and false positives (FP).  The EQA 
process led by the Ethiopian Public Health Institute (EPHI) and funded and supported by 
the CDC was the gold standard. Training and mentoring laboratory professionals and 
instituting internal quality assurance (IQA) occurred during the period between 2012 and 
2014 and the FP rate declined from 0.6% to 0.2%, and the FN fell from 7.6% to 1.6%. 
Melese et al. (2016) said that direct sputum microscopy for AFB using light microscopy 
is a test predominantly used to detect bacteria worldwide. The test is cost-effective, easy 
to train people to perform, and does not require a sophisticated instrument. But sputum 
microscopy for AFB heavily relies on external and internal QA, continuous quality 
improvement programs, and a reliable source of reagents. 
Fonjungoa et al. (2012) said that laboratories should follow standard operating 
procedures with functioning equipment to obtain reliable and reproducible results that 
maintain turnaround time. Birhanaselassie (2015) said that laboratory service facilities 
and health facilities in Ethiopia have been reported to be very weak and limited. 




follow-up and supervision by hospital managers and governmental health agencies. These 
gaps are directly linked to ineffective laboratory processes. Clinical laboratories are an 
essential part of the healthcare system. Failed laboratory management systems can lead to 
unreliable diagnostic methodologies and inappropriate treatment, which can lead to 
increased morbidity and mortality (Birhanaselassie, 2015). Often, LMIC laboratories 
receive highly sophisticated laboratory instruments such as the Gene Xpert instrument at 
a reduced price. However, they usually have limited power to negotiate for low-cost 
consumables and employee training, so potential improvements in laboratory capabilities 
are often not realized. 
The two most commonly-used microscopic procedures to recover TB organisms 
from a sputum sample are conventional ZN microscopy and fluorescence microscopy. 
Fluorescence microscopy is more sensitive (10%) and takes less time (WHO, 2011). 
However, it requires expensive mercury vapor light sources with regular maintenance and 
a dark room, which makes it inaccessible in most resource-limited countries. The WHO 
(2011) said LED microscopy was developed mainly to give resource-limited countries 
access to the benefits of fluorescence microscopy. LED microscopes are available in 
Ethiopia; they are less expensive, require less power, and can run on batteries. 
As part of SDGs to end the global TB epidemic by 2030, the Strategic and 
Technical Advisory Group for Tuberculosis (STAG-TB) provides technical guidance to 
the WHO.  The STAG-TB provides objective, ongoing technical, and strategic advice to 
the WHO related to TB care and control.  The WHO (2016d) supported the inclusion of 




program planning at every level. The literature review indicates shortages of laboratory 
consumables and lack of close follow-up and supervision from managers and 
governmental health agencies leads to incomplete and delayed laboratory results.  The 
proposed study will reiterate the importance of engaging local laboratory professionals 
and managers and empowering them to own laboratory support processes. Highly 
advanced technology might not always be fitting. The study can encourage and educate 
Ethiopian laboratorians and managers to consider local resources before adapting TB 
laboratory methods. Building confidence in laboratory managers to be decision-makers in 
their local area will lead to positive social change.  
Haile et al. (2014) said that the level of commitment among laboratory managers 
in Ethiopia varies and affects the continuity of good laboratory practice. Haile et al. 
(2014) said that there is a country-wide problem regarding purchasing of reagents, 
laboratory consumables, and quality control materials.   
Addis et al. (2013) said that 86.7% of physicians and nurses in Ethiopia have 
encountered lost laboratory reports. Loss of laboratory results were not directly 
associated with the healthcare provider’s level of dissatisfaction. However, it represents a 
possible compromise in providing timely treatment to patients.  
Mala, Moser, Dinant, and Spigt (2014) conducted a study in Tigray, Ethiopia to 
understand why TB service providers in Ethiopia do not follow treatment guidelines. 
Thirty-nine TB care providers participated in a focus group discussion. Healthcare 
providers  developed negative expectations about the results of sputum smear microscopy 




first is Ethiopia’s limited ability to correctly diagnose TB and give the right treatment. 
Second is the lack of clarity of local guides with recommendations when to retest those 
patients whose initial tests are negative. Third is the lack of complete diagnosis and 
treatment documentation. Also, there are five factors that influence noncompliance 
among TB care providers: insufficient diagnostic modalities, ambiguity in guidelines and 
recommendations, poor patient care documentation, state of healthcare services, and 
healthcare providers in government-run or private hospitals showing little interest in 
following national guidelines.   
 Fiseha and Demissie (2015) emphasized the importance of decentralized TB 
treatment centers in Ethiopia. Patients are not able to comply with direct observation 
treatment (DOT) because treatment centers congregate in the city, away from the rural 
community. Moreover, enhanced severity of the disease when co-infection with HIV 
reduces adherence.  The study also gives insights about factors that influence TB 
treatment adherence. One is the patient’s belief about the curability of TB disease.  
Second is support from family, friends, the community, and health professionals, all of 
whom can help the patient to seek treatment and adhere to the medication regimen.       
Temesgen and Demissie (2014) conducted a study in the Amhara region in 
northwestern Ethiopia to assess the knowledge and practice of M. tuberculosis infection 
control (TBIC).  The study involved 313 healthcare providers in four hospitals. In the 
study, TBIC knowledge and practice were used as dependent variables. Independent 
variables establishing TBIC knowledge and practice were sociodemographic 




and training regarding TBIC. Knowledge about TBIC was a strong predictor of good 
TBIC practice. Only 18% of participants were trained on TBIC. Years of service or level 
of education was not associated with TBIC knowledge.  Even though there was a high 
prevalence of TB with a high probability of TB nosocomial transmission, most health 
facilities in Ethiopia do not have TBIC practices.  Therefore, patients and providers are at 
risk of exposure to TB, especially at high caseload facilities.   
 Fiseha and Demissie (2015) found that healthcare workers (HCWs) shared their 
concern about contracting TB/MDR-TB due to the absence of standard TB IC measures. 
Given the high cost of infection control processes, most low-income countries cannot 
afford to implement them. 
 Kivihya-Ndugga et al. (2004) discussed Nairobi, Kenya, where sputum 
specimens from 1, 396 TB suspected patients were analyzed for the presence of TB using 
the PCR assay. The result showed a sensitivity and specificity at 93% and 84%, 
respectively. The concern is the cost-effectiveness and operational effectiveness for low-
income countries with high-burden of TB.   
Scherer et al. (2004) said when using culture as a gold standard, a sensitivity 
ranges from 77% to more than 95%.  However, for smear-negative specimens, PCR 
sensitivity has been reported to be below 90%. Scherer et al. (2004) also examined 
sensitivity for HIV positive versus HIV negative patients, showing lower sensitivity for 
HIV positive patients. 
Definitions  




Acid-fast bacilli (AFB): is a type of bacteria that causes tuberculosis and certain 
other infections (WHO, 2010). 
Colour test: A simplified and more timely TB culture method when compared 
with traditional culture methods.  It was designed to assist with more timely confirmation 
of TB infections, particularly in low resource settings. The colour test combines the thin-
layer agar technique with a simple colour-coded quadrant format, selective medium to 
reduce contamination and colorimetric indication of bacterial growth to simplify 
interpretation. DST patterns for isoniazid (INH), rifampicin (RMP), and ciprofloxacin 
(CFX) were determined using the Colour Test for 201 archived Mycobacterium 
tuberculosis isolates.     
Extensively-Drug Resistant Tuberculosis (XDR-TB): A form of multidrug-
resistant TB with additional resistance to more anti-TB drugs that therefore responds to 
even fewer available medicines. It has been reported in 117 countries worldwide (WHO, 
2017c).Xpert MTB/RIF Assay: A qualitative, nested real-time PCR in vitro diagnostic test 
for the detection of TB complex DNA in raw sputum.  In specimens where MTB-
complex is detected, the Xpert MTB/RIF assay also detects rifampin-resistance 
associated with mutations of the rpoB gene (WHO, 2017c).   
Latent TB Infection: TB bacteria can live in the body without making a person 
sick. In most people who breathe in TB bacteria and become infected, the body can fight 
the bacteria to stop them from growing. Latent TB infections can activate to become TB 




Multi-Drug Resistant Tuberculosis (MDR-TB): The bacteria that cause TB can 
develop resistance to the antimicrobial drugs used to cure the disease. MDR-TB is TB 
that does not respond to at least isoniazid and rifampicin, the two most powerful anti-TB 
drugs (WHO, 2017c). 
TB-LAMP: A manual assay that requires less than one hour to perform and can be 
read with the naked eye under ultra violet light. The WHO (2016c) recommended that the 
TB-LAMP can be used as a replacement for microscopy for the diagnosis of pulmonary 
TB in adults with signs and symptoms of TB. 
Xpert MTB/RIF: An automated, cartridge-based nucleic amplification assay for 
the simultaneous detection of TB and rifampicin resistance directly from sputum which 
takes less than 2 hours (WHO, 2017a). 
Ziehl-Neelsen (ZN) Stain:  A smear prepared directly from sputum specimens and 
it is the most widely available test for diagnosis of TB in resource-limited settings. ZN 
microscopy is highly specific, but its sensitivity is variable (20-80%) and is significantly 
reduced in patients with extrapulmonary TB or HIV (WHO, 2010).  
Assumptions 
According to the WHO (2017b), there is a global caution practiced when using 
country health information system (HIS), including vital registration because of concerns 
with information/data quality and completeness. The WHO emphasized the need to 
strengthen each country’s HIS, in-order to provide a more solid empirical basis for 
monitoring the national health situation and trends. The first and primary assumption of 




The second assumption of this proposed study is that undocumented information 
on the health center log reflects incomplete laboratory work. It is not clear if the patient 
refused to submit sputum specimen or employees did not give adequate specimen 
collection instruction to the patient.  It may be the patient could not produce sputum 
specimen. It is not clear if there was no designated area for the patient to collect the 
specimen. The WHO (2017c) affirmed that the global health estimates represent the best 
estimate by the WHO based on the evidence available to it.   
Scope and Delimitations  
The study was based on secondary data obtained from a community health center 
in Addis Ababa, one of the largest cities in Ethiopia. Addis Ababa is an urban city with 
adequate roads, transportation system, and has an accessible healthcare system. 
Therefore, the city is not representative of most towns in Ethiopia.   
 One limitation of the study involves obtaining reliable data. Most data received 
from local areas are estimates. Therefore, many international agencies, including the 
WHO confirmed that available data are at best an estimate. Therefore, another limitation 
is an incomplete result documentation process. The secondary data from the community 
health center TB laboratory in Addis Ababa may reflect gaps in the specimen collection 
and documentation of laboratory results. 
Summary and Conclusion 
Clinical laboratories are an integral part of a healthcare system. Laboratories play 
a significant role in the diagnosis of a disease. The need to standardize laboratory 




delay diagnosis and treatment. However, once the patient arrives at the laboratory, 
patients must receive full service. A failure to give full laboratory service is a lost 
opportunity to diagnose and treat a patient.  
The proposed study can provide an evaluation of the day-to-day activities of a 
community health TB laboratory revealing the success and the challenges faced even 
with the availability of high-technology instruments, like the Gene Xpert MDR-RIF-R 
PCR assay.  
It is considered vital to building on what a laboratory can achieve using current 
procedures before moving into the use of instruments that require technical assistance. 
Assessing, understanding, and revising existing procedures will require direct 
participation from the local laboratory management group with the support of 
international health agencies. The study will also recommend ways to improve the 
current processes.  The suggested procedures will build on what Ethiopia already 




Section 2: Research Design and Data Collection 
Introduction 
This study involves the evaluation of the collection and analysis of specimens 
once the patient arrives in laboratory to complete and release TB test results for 
laboratory technicians. The study examined and reported proper documentation of each 
step during the laboratory process. The design choice advances the importance of 
attention to details at each step of the laboratory process. 
There are many laboratory processes and procedures to diagnose TB. TB may be 
present in sputum, gastric lavage fluids, cerebrospinal fluid, urine, and a variety of 
tissues. One procedure that is widely used is the AFB microscopic test. The purpose of 
AFB microscopy is to detect AFB through microscopic examination of clinical 
specimens.  The light microscopy of ZN staining is prepared directly from sputum 
specimens. The method is a widely used test for diagnosis of TB in resource-limited 
settings.  
     The laboratory test starts with collecting sputum samples, followed by staining 
and microscopic analysis to determine the absence or presence of AFB organisms. The 
Xpert MTB/RIF PCR assay was recommended by the WHO in 2015 to be used as an 
initial diagnosis for all people suspected to have pulmonary TB.  To understand the 
challenges faced by a health center in Addis Ababa, Ethiopia this study examined TB 
laboratory procedures at one of the TB laboratories in the area.   
The variables under study are the number of specimens collected, TB microscopic 




indicated in laboratory records. Data records are identified numerically as 1 through 160 
participants. 
Research Design and Rationale 
The goal of the study was to investigate the potential challenges of TB 
laboratories. The study applied the descriptive quantitative research design to assess 
incomplete laboratory steps and test results based on a sample size of 160 laboratory 
records  from between August 2015 and December 2016. Laboratory records involved 
numerical identifiers to itemize variables. The study analyzed secondary data obtained 
from a community health center TB laboratory in Addis Ababa to perform descriptive 
statistics for the collection of sputum specimen from TB-suspected patients, tresults ZN 
microscopic tests, and the Gene Xpert instrument to detect MDR- TB. Since this study 
used secondary data and there were no inferential research questions, the descriptive 
quantitative design was most appropriate. 
Methodology  
The study objective was to determine adherence to standardized TB laboratory 
procedures, using SPSS descriptive analysis and frequencies, which includes frequency 
analysis for variables, number of specimens collected from TB-suspected patients, 
sputum smear TB microscopy test results, and MDR-TB testing results using the Gene 
Xpert instrument as indicated in laboratory records. Data records were identified 
numerically.  
The dataset was identified using numerical numbers with a sample size of 




the fact that all data were included in the statistical analysis and there were no inferential 
statistics, effect size and statistical power cannot be calculated.    
Descriptive statistics and frequency table options allow the analysis of each coded 
step to calculate frequency and a corresponding graph to visually represent how the 
laboratory adhered to TB processing and resulting procedures set by the WHO. 
Descriptive statistics include the number of processes that were resulted, not documented, 
flagged as errors, or showed invalid results (error, invalid, undocumented, specimen not 
collected) as part of the study. More specifically, the percentage of valid/documented 
results when performing the ZN stain test and MDR-TB test for each suspected TB 
patient was evaluated to see if they met WHO criteria; 5-15% error/undocumented results 
are acceptable (WHO, 2015a). For failed laboratory steps, the study will make a 
recommendation for improvement.  
The research questions for this study are: 
RQ1: During the period between August 1, 2015 and December 31, 2016 at a 
community health center TB laboratory in Addis Ababa, what was the number of sputum 
samples for detection of mycobacterium tuberculosis for suspected TB patients?  
RQ2: Between August 1, 2015 and December 31, 2016 at a community health 
center TB laboratory in Addis Ababa, what was the percentage of valid/documented 
results when performing the laboratory ZN stain test for suspected TB patients?     
RQ3: During the period between August 1, 2015 and December 31, 2016 at a 




valid/documented results when performing laboratory MDR-TB tests for suspected TB 
patients?  
Data Analysis 
Variables and codes under study are displayed in Table 2. More specifically, 
Table 2 includes information regarding the number of specimens collected, TB 
microscopic test results, and TB and MDR-TB test results using the Gene Xpert 
instrument, as indicated in laboratory records. All variables are categorical; therefore, 
descriptive statistics include frequency percentages for each code per variable. 
Additionally, for ZN and MDR-TB tests, a ratio of valid results was reported (number of 
valid documented cases/all cases). All analyses were conducted using SPSS v. 24.  
The laboratory is required to collect three sputum samples from each TB- 
suspected patient.  The laboratory is also required to perform ZN staining for each 
sputum and record microscopic results for each sputum sample. In addition, the 
laboratory is also required to perform MDR-TB test using the Gene Xpert PCR 
instrument for each MDR-TB suspected patients.  Collecting three sputum samples and 
performing ZN stains for each sputum sample and microscopic reading to obtain and 
document three ZN stain results for each TB patient is required. In addition, Gene Xpert 
PCR test results are required for all MDR-TB suspected patients. 
  
The study assessed the percentage of failed test. For example, if no test result is 
documented, if invalid test result documented, and error test result is documented. The 




test. The study was limited to assessing the performance of the laboratory only. The study 
does not assess or confirm patient diagnosis or treatment. 
Table 2 
 
Study Variables and Codes 
Variables  Codes 
Number of sputum 
specimen collected from 
each TB infection 
suspected patient 




4- Not documented 
 
ZN stain sputum 
microscopic test result 
 1- Negative 
2- 1-9 + 
3- 10-99 ++ 
4- >= 100 +++ 
5- Not Documented 
  
MTB/RIF Assay results 
using the Xpert PCR 
instrument   
 0- TB Detected 
1- TB Not Detected 
2- TB Detected RIF Detected 
3-  TB Detected RIF Not 
Detected 
4- Instrument Error/invalid 
5- Not documented 
 
Threats to Validity 
A secondary analysis examines data that were primarily collected for some 
purpose other than the research studies. Secondary data will expedite and strengthen this 
proposed research study. Secondary data will support the doctoral research as the data 
will help develop, answer, and elaborate upon the research question. Result of a research 
study is vital to the degree that it can be interpreted accurately and confidently. Accurate 




I analyzed the frequencies of events to establish a high occurrence of disagreeable 
laboratory events that might affect patient health outcomes. The study result was valid 
since it reflects the rate of laboratory results obtained and the frequency of undocumented 
result and failed results. The study does not calculate associations between variables, and 
thus no internal validity threats exist. Additionally, I do not generalize the results of the 
study to other populations, since they are useful to evaluate TB data collection and 
analysis procedures only in Ethiopia. The only threat to this study can be potential issues 
with the secondary data, such as missing cases or incomplete data and I worked with the 
health center to address these issues as much as I could. 
 Ethical Procedures  
Research should always be conducted ethically.  It is important to get the required 
permission when a research study involves human subjects and accessing patient health 
information. This study was conducted using a secondary data set without any direct 
interaction with patients, and no patient identifiers are used. The laboratory record used 
numerical identifiers to itemize variables. I received approval by Addis Ababa University 
Research Review Board (AAURRB) to receive and analyze the data. Additionally, 
Walden IRB also approved this study (#12-17-19-0466211). All data will be stored in 
password-secured files in my computer for at least 5 years per Walden policy. 
Summary  
Clinical laboratories are an integral part of a healthcare system. Laboratories play 
a significant role in the diagnosis of a disease. The need to standardize laboratory 




delay diagnosis and treatment. However, once the patient arrives at the laboratory, 
patients must receive full service. A failure to give full laboratory service is a lost 
opportunity to diagnose and treat a patient. The study objective is to determine adherence 
to standardized TB laboratory procedure using SPSS which includes frequency analysis 
for variables, number of specimens collected from each TB suspected patient, sputum 
smear TB microscopy test results, and MDR-TB testing results using the Gene Xpert 




Section 3: Presentation of the Results and Findings 
Introduction 
The study used a quantitative descriptive design to determine levels of 
adherence in a community health center TB laboratory in Addis Ababa, Ethiopia to 
standardize TB laboratory procedures. The study involved sputum samples from each 
suspected TB patient, and the valid/documented results of laboratory ZN stain test and 
MDR-TB test for each suspected TB patient at the center under study.  
RQ1: During the period between August 1, 2015 and December 31, 2016 at a 
community health center TB laboratory in Addis Ababa, what was the number of sputum 
samples for detection of mycobacterium tuberculosis for suspected TB patients?  
RQ2: Between August 1, 2015 and December 31, 2016 at a community health 
center TB laboratory in Addis Ababa, what was the percentage of valid/documented 
results when performing the laboratory ZN stain test for suspected TB patients? 
RQ3: During the period between August 1, 2015 and December 31, 2016 at a 
community health center TB laboratory in Addis Ababa, what was the percentage of 
valid/documented results when performing laboratory MDR-TB tests for suspected TB 
patients?   
Data Collection of Secondary Data Set 
The study used secondary data collected by the TB laboratory from August 1, 
2015 to December 31, 2016. Patients who come to this laboratory are suspected of having 
TB infections, and they are referred by primary care physicians to submit sputum samples 




transportation; therefore, patients in Addis Ababa have the option of using a city train or 
taxi. The TB laboratory is a government-run laboratory, and patients are charged a 
reduced fee for laboratory services compared to private laboratories.   
Results  
      The variables under study are the number of specimens collected, TB microscopic 
test results, and TB and MDR-TB test results using the Gene Xpert instrument, as 
indicated in laboratory records. Data records were identified numerically as 1 through 
162. 
Descriptive statistics data analysis was performed using SPSS version 25.  All 
variables are categorical and reported as frequencies (%).   
In Table 3, 1.2% of the sample was RMP detected and 2.5% was RMP resistant 
indeterminate. It is indicated that in 86.4% of the sample, tests were not performed, and 
of 13.6% test that was performed, 2.5% were recorded as errors.   
Table 3 
 
Frequency Table for MTB-RIF Assay Xpert Instrument 
 Frequency Percent Valid 
Percent 
  
 TB not detected 12 7.4 7.4   
TB detected RMP resistant 
detected 
2 1.2 1.2   
TB detected RMP resistant not 
detected 
4 2.5 2.5   
Error 4 2.5 2.5   
Not performed 140 86.4 86.4   
Total 162 100.0 100.0  
 
For 4.4% and 21.5% of participants’ two sputum samples and one sputum sample were 




48.1% of the study population and 25.9% of patients for whom no sputum samples were 
provided.      
Table 4 
 




Percent   
 0 41 25.3 25.9  
1 34 21.0 21.5  
2 7 4.3 4.4  
3 76 46.9 48.1  
Total 158 97.5 100.0  
Missing System 4 2.5   
Total 162 100.0   
 
In addition, Tables 5, 6 ,and 7 show that for samples 1, 2, and 3there were results only for 
72.2%, 51.2%, and 47.5% of study participants, respectively, and for the rest no 
evaluation was peformed.  
Table 5 
 
Frequency Table: Sample 1 
 Frequency Percent Valid 
Percent 
 
 no + 106 65.4 65.4  
+ 1 .6 .6  
++ 6 3.7 3.7  
+++ 4 2.5 2.5  
Not 
performed 
45 27.8 27.8  


















 no + 75 46.3 46.3  
 + 2 1.2 1.2  
 +++ 6 3.7 3.7  
 Not 
performed 
79 48.8 48.8  









 no + 69 42.6 42.6  
 ++ 4 2.5 2.5  
 +++ 4 2.5 2.5  
 Not 
performed 
85 52.5 52.5  
 Total 162 100.0 100.0  
 
Summary 
For RQ1, where the number of sputum specimens collected was evaluated for 
each suspected TB patient, an optimal number of three samples was submitted only for 
48.1% of the study population and no sputum were provided for 25.9% of patients.       
For RQ2, where the percentage of valid/documented results for samples 1, 2, and, 
3 when performing the laboratory ZN stain test for each suspected TB patient was 
evaluated there were results only for 72.2%, 51.2%, and 47.5% of study participants, 




For RQ3, where the percentage of valid/documented results when performing the 
MDR-TB test for each suspected TB patient was evaluated, it was indicated that in 86.4% 
of the sample, the test was not not performed and among 13.6% of that population, 2.5% 
was recorded as having errors. For all research questions, WHO criteria for 5-15% 




Section 4: Application to Professional Practice and Implications for Social Change  
Introduction and Key Findings 
The principal purpose of this study was to determine level of adherence to 
standardized TB laboratory procedures by calculating and reporting the number of 
sputum samples from each suspected TB patient, as well as valid and documented results 
of ZN stain tests and MDR-TB tests for each suspected TB patient at a community health 
center TB laboratory in Addis Ababa, Ethiopia. In this section, I will provide the key 
results for each research question and how these results compare to WHO criteria.  
 For RQ1, where the number of sputum specimens collected was evaluated for 
each suspected TB patient, the optimal number of three samples was submitted only for 
48.1% of the study population, and no sputum was provided for 25.9% of the patients. 
For RQ2, where the percentage of valid and documented results for samples 1, 2, and, 3 
when performing the laboratory ZN stain tests for each suspected TB patient was 
assessed, there were results only for 72.2%, 51.2%, and 47.5% of study participants, 
respectively, and for the rest no evaluation was performed. Therefore, the WHO criteria 
of 5-15% error/undocumented results were not met. In exploring RQ3, for which the 
percentage of valid and documented results when performing the MTB-RIF-TB test for 
each suspected TB patient was evaluated, 86.4% of the sample MTB-RIF-TB test was not 
performed; this is significantly high compared to WHO criteria of 5-15% for error and 
undocumented results.   
Second, I will compare these data to similar data reported by the WHO and other 




discussed potential deviations from these standards. In this section, I will discuss the 
results of the study compared to the WHO and Sub-Saharan African countries with 
similar demographics. Second, I will discuss these results based on the theoretical 
framework I suggested in Section 1. In this section, I will also discuss interpretations of 
the study results in relation to the theoretical framework. I will also discuss and compare 
TB laboratory studies and results from other Sub-Saharan countries.    
Interpretation of the Results 
Onyebujoh et al. (2017) said that Africa is home to 26% of estimated incidences 
of all TB cases (2.7 million) and TB death rates in Africa are three times greater than the 
global average. Summer et al. (2019) said it is sometimes assumed that the only 
constraint is the health sector budget; however, even if funding is available, it may take 
time to allocate necessary staffing and infrastructure to deliver TB services.  Improving 
equitable access to TB diagnosis and treatment remains the most pressing need for 
Africa, where laboratory services play a pivotal role (Onyebujoh et al., 2017).  
Since 2011, investments in molecular TB diagnostics have multiplied, as reflected 
by the deployment of an increasing number of Cepheid GeneXpert systems across Africa. 
However, these efforts were not being translated into an increased diagnosis of TB cases 
or increased laboratory confirmations of cases that were notified (Onyebujoh et al., 
2017). 
Onyebujoh et al. (2017) said  that the numbers of laboratories providing TB 
diagnostic services using smear microscopy and GeneXpert have gradually increased. 




increased. As a more sensitive and accurate molecular diagnostic tool, the potential of 
GeneXpert technology to improve the diagnosis of tuberculosis/HIV cases has yet to be 
fully realized since it was introduced in 2011. 
Summer et al. (2019) said in South Africa, mathematical models are increasingly 
being used to compare strategies for TB control without detailed information regarding 
implementation. Decision-makers need information about local resources, infrastructure, 
culture, practices, needs, and wants of the local area.  
  For RQ1, three samples were submitted only for 48.1% of the study population, 
and for 25.9% of the patients, no sputum samples were provided. In some cultures, 
people may need a covered area or a room to collect sputum samples, and in many 
resource-limited countries, restrooms are not always available. Testing three samples can 
increase the sensitivity of TB diagnosis to 90.2% (Sujata, 2014).  
Dzodanu et al. (2019) said that in many developing countries, the diagnosis of TB 
is mostly based on the ZN staining technique.  The ZN method, however, is reported to 
be low and variable, ranging from 20 to 80%, often depending on the diligence with 
which specimens are collected, smears are made, and stained smears are examined.  The 
WHO guideline is to collect three specimens per patient. Parsons et al. (2011) said 
examination of only two smears in place of three could ease the workload of laboratories, 
decrease time for diagnosis and initiation of treatment, and decrease the number of 
patients dropping out of the diagnostic pathway by one third, particularly in countries 
with a high microscopy workload. In addition, patients will spend less time at the 




screening of TB patients from three to two specimens should be recommended only in 
settings with a well-established laboratory network and fully-functional EQA program for 
smear microscopy, including onsite evaluation and followup training for problem 
laboratories. Also, reducing the number of sputum specimens collected may leave a 
significant number of cases undetected, especially if it becomes the only means of 
diagnosis.   
RQ2 involves the percentage of valid and documented results when performing 
laboratory ZN stain tests for each suspected TB patient. My study revealed that the 
results for samples 1, 2, and, 3 when performing the laboratory ZN stain test for each 
suspected TB patient, were only 72.2%, 51.2%, and 47.5% of study participants, 
respectively, and for the rest no evaluation was performed. This negative result highlights 
the importance of a reliable support system that includes training. Haile et al. (2014) said 
that there is a country-wide problem regarding the purchasing of reagents, laboratory 
consumables, and quality control materials. Merton’s theory of unintended consequences 
of social action is useful to investigate how decision-makers decide what is beneficial for 
a local area. Solinas-Saunders and Stacer (2015) said that many factors are intertwined, 
and the choices are formed within a social context constrained by time and space. One’s 
action rationality is a function of their interpretation of reality in the context of a social 
system (Merton, 1936). In 22 high burden countries (of which Ethiopia is one) with 80% 
of tuberculosis cases worldwide, a systematic review of 37 eligible studies of serial 
sputum specimen results indicated that almost 85.8% of TB cases were detected with the 




was 11.9%, while the incremental yield of the third specimen, when the first two 
specimens were negative, was 3.1%.       
 RQ3 regarding the Gene-Xpert instrument test indicated that in 86.4% of the 
sample, the test was not performed, and of 13.6 % test that was completed, 2.5% was 
recorded as an error. The Xpert MTB/RIF PCR assay was recommended by the WHO in 
2015 to be used as an initial diagnosis for all people suspected to have pulmonary TB). 
Xpert MTB/RIF is an automated, cartridge-based nucleic amplification assay for the 
simultaneous detection of TB and rifampicin resistance directly from sputum in less than 
two hours (WHO, 2017a). However, the presence of a reliable support system that 
includes training, infrastructure, and timely technical backing is highly recommended to 
make the PCR testing worthwhile. Summer et al. (2019) discussed the critical impact and 
cost-effectiveness of TB case detection, where sometimes it is assumed that the only 
constraint is the health sector budget. However, even if funding is available, it may take 
time to allocate the necessary staffing and the infrastructure to deliver TB services. Rice 
(2017) stated that the detection of  (MTBC and RIF resistance has been well documented 
in low-resource settings with high TB-incidence. However, few studies have assessed its 
accuracy in low TB incidence settings with high resources. A retrospective study 
evaluated the performance of Xpert MTB/RIF using clinical sputum specimens routinely 
collected from suspect pulmonary TB patients in San Diego County, California. Xpert 
MTB/RIF results were compared to acid-fast bacilli (AFB) smear microscopy, 
mycobacterial culture, and phenotypic drug susceptibility testing (DST) (Rice 2017). In 




for PCR testing to be performed on at least one respiratory specimen, from each patient 
with signs and symptoms of pulmonary TB. In general, the Xpert MTB/RIF assay was 
used to test the first AFB smear-positive specimen collected from each patient, as well as 
AFB smear-negative specimens per clinician request in patients with a high suspicion of 
pulmonary TB. Of 751 sputum specimens, 134 (17.8%) were MTBC culture-positive and 
2 (1.5%) were multidrug-resistant (MDR) (Rice 2017). 
Xpert MTB/RIF detected 35 of 47 smear-negative culture-positive specimens 
and excluded 124 of 137 smear-positive culture-negative specimens. Xpert MTB/RIF 
also correctly excluded 99.2% (121/122) of nontuberculous mycobacteria (NTM) 
specimens. It also eliminated all 33 NTM false-positives by smear microscopy. Xpert 
MTB/RIF sensitivity and specificity for the detection of RIF resistance were 100% (2/2) 
and 98.3% (116/118), respectively (Rice, 2017). The success of such scenario under-
scores the availability of an in-built infrastructure in developed countries, that might be 
taken for granted while implementing high-tech instruments in developing countries. 
More often the lack of funding for such project might sufficiently been addressed 
however, it might not only be a lack of funding, Summer et al. (2019) discuss the critical 
impact and cost-effectiveness of TB case detection, where sometimes it is assumed that 
the only constraint is the health sector budget. However, even if funding is available, it 
may take time to allocate the necessary staffing and the infrastructure to deliver TB 
services.  
The study by Ardizzoni et al. (2015) describes the performance of Xpert and 




projects located in 18 countries supported by Médecins Sans Frontières across varied 
geographic, epidemiological and clinical settings.  Routine laboratory data were 
collected, using laboratory registers. Qualitative data such as logistics, human resources, 
and methodology approval were collected using a questionnaire. First, Xpert was used as 
the initial test, with microscopy in parallel, for all possible TB cases. Second Xpert was 
used for patients at risk of MDR-TB, or with HIV associated TB, or presumptive 
pediatric TB; and the third Xpert was used if test is the initial test for high-risk patients as 
an add-on test to microscopy. The average MTB detection rate was 18.5%, 22.3%, and 
11.6% for the above three different tests, respectively. 
The results microscopic tests in parallel with Xpert as an add-on test to 
microscopy test increased laboratory TB confirmation by 49.7%. The major drawback of 
the test was the high rate of inconclusive results, which correlated with factors such as 
defective modules, cartridge version (G3 vs. G4), and staff experience. Operational and 
logistical hurdles included infrastructure renovation, basic computer training, regular 
instrument troubleshooting, and maintenance, all of which required substantial and 
continuous support (Ardizzoni et al. 2015). 
Considering the results from these studies, we are confident the challenges faced 
in low-resource settings with high TB-incidence, needs attention to address the lack of 
comprehensive technical assistance, including the formulation of policies, infrastructure 




Study Results and Theoretical Framework 
 It is essential to investigate that diagnostic tools are accurate and supported by 
available resources in the local area to have a direct impact on case prevention and saving 
a life. Merton (1936) explains this situation that decision-makers act rationally by 
selecting a means based on the available evidence, and yet the goal may not be attained. 
Merton (1936) further explains that the most obvious limitation to correct anticipation of 
consequences of an action is the existing state of experience. Therefore, limited 
knowledge can be the sole barrier to correctly anticipating a future outcome. Solinas-
Saunders and Stacer (2015) said that some health interventions carry unintended 
consequences that are unpredictable while some are seen and prevented. For example, if 
we apply Merton’s theory of compassion for those marginalized (poverty-stricken TB 
patients), it often motivates purposive social action. Based on Merton’s theory of 
unintended consequence of purposive action, the demand for social engagement is 
pressing, as is the need for immediate results. 
According to Merton’s theory, available knowledge is another way in which 
decision-makers’ conclusions are restrained. When trying to decide what type of 
treatment, diagnostic procedure, or medical equipment is appropriate, decision-makers 
need information about local resources, culture, practices, needs, and wants of the local 
area.  They lack knowledge, or their ability to translate knowledge into empirical data 
with the need to obtain immediate results limits the ability to predict the outcome with 




The issue of the country’s limited infrastructure, insufficient technical training, 
and limited troubleshooting abilities of laboratorians need to be considered in full before 
making any decisions. It is also crucial to investigate the availability of infrastructure 
capabilities, training, and technical support. These activities should be determined, 
sustained, and be managed by the country's local health department managers with the 
total backing by decision-makers and international agencies. 
Xpert MTB/RIF Studies in Sub-Saharan Africa 
 In 2010, the WHO endorsed the use of Xpert MTB/RIF, a rapid diagnostic assay 
that can identify Mycobacterium tuberculosis and resistance to rifampicin. WHO 
recommendation included the use of Xpert MTB/RIF as a primary diagnostic test for 
adults with suspected drug-resistant TB, for children and adults with suspected TB in 
settings with high HIV prevalence, and the detection of extra-pulmonary TB. Resources 
permitting, Xpert may also be used as an initial diagnostic test for all patients with 
suspected TB or as a follow-on test to microscopy for adults with smear-negative results 
(WHO, 2011a).  
In 2014, 4.8 million Gene Xpert cartridges were acquired in the public sector in 
116 countries of the 145 countries eligible for concessional pricing, and Ethiopia was one 
of these countries (Umubyeyi et al. 2016). Its availability at lower-level health facilities 
like Community health TB laboratory is an added benefit to improving access to testing. 
However, Umubyeyi et al. (2016), states that studies and models have presented potential 
uses and impacts of the test. Still, few results have been published on the implementation 




Umubyeyi et al. (2016) state that the implementation of Xpert was conducted in 
five Sub-Saharan African countries. It was done in collaboration with the US Agency for 
International Development, the African Society of Laboratory Medicine, the WHO and 
the Global Fund to Fight AIDS, Tuberculosis, and Malaria in five Sub-Saharan African 
countries, which are, the Republic of Congo, Eritrea, Ethiopia, Ghana, and Kenya.  
The study results from two countries illustrate the direct impact of these 
interventions: in Kenya, 8221 Xpert tests were conducted in 2015, of which 1830 
(22.3%) were positive for M. tuberculosis, and 81 (4.4%) were rifampin resistant. In 
Ethiopia, evaluation after the first year of implementation (July 2013–December 2014) 
showed a 22% increase in the number of drug-resistant TB cases detected, while total TB 
cases detected rose from 58 802 to 63 168 (7.5%). The contribution of Xpert to TB case 
detection was 2% (source: Ethiopia National TB Program, 2015). Regarding the impact 
of Xpert on patient care, the study state that there are no significant or systematic 
improvements linking diagnosed patients to treatment. Generally, empirical treatment   
remained the rule, even with the availability of additional information about drug 
resistance, for example, with Xpert MTB/RIF testing. Overall, the utilization of the Xpert 
machines was at 15% of full capacity, representing a missed opportunity to diagnose 
potential TB and drug-resistant TB cases due to poor referral and transport systems. 
Umubyeyi et al. (2016) state to achieve the maximum impact from innovative 
diagnostics systems, like Xpert, countries should improve the quality of health care, 
commit the resources needed, and implement a strategic plan for laboratory services and 




Community Health Center TB Laboratory showed a need for attention to details that can 
come from a commitment and involvement of the local laboratory experts with 
knowledge and experience. 
Social Change 
Due to limited access to a well-developed health insurance system, about 80 % of 
private health expenditure in Ethiopia is via Out of Pocket Payments (OOPs,) and private 
insurance institutions cover only 1.5 % of private healthcare expenditure. Providing 
healthcare to individuals working informally or who live in rural areas is a significant 
challenge in developing countries (Badacho et al., 2016).  
Considering the challenges faced by government health facilities and by the 
patient in developing countries, the proposed study at the Community Health Center TB 
laboratory will evaluate TB laboratory procedures and share its findings. The laboratories 
must provide detailed and complete laboratory test results once the patient managed to 
travel to the Community Health Center and paid out-of-pocket charges. The situation 
might erode patient’s confidence and affect their compliance of submitting required 
samples for laboratory tests. Undiagnosed infection creates a cycle of disease leaving the 
country’s population vulnerable by spreading the infection to family and community 
members. 
 TB laboratory processes need to be structured, systematized, and entirely led by 
local laboratory managers and Directors, supported by government officials and 




laboratory managers to be engaged and make sound decisions based on local resources is 
a positive social change.  
Limitation of the Study 
Global health estimates represent the best estimate by WHO based on the 
evidence available to it. Clinical laboratories are part and parcel of the healthcare 
services; in that respect, the proposed study results will be shared with the FDRE MOH. 
The study result can be extrapolated to represent other urban cities in Ethiopia to give 
insights to TB laboratory professionals and managers. However, this study population is 
not representative of all regions in Ethiopia, especially the rural areas. 
Recommendations 
It is vital to evaluate what a laboratory can achieve using the current procedures 
before starting to use an instrument that requires high technical assistance. Assessing, 
understanding, and revising existing procedures will require direct participation from the 
local laboratory management group with the support of international health agencies.     
The study recommends a direct and step by step participation of local laboratory 
professionals and laboratory managers to decide which laboratory instrument or 
procedure will work best to enable them to complete and obtain a valid result for each 
laboratory test. The study also recommends that local laboratory professionals and 
laboratory managers should plan a test validation process using a previously confirmed 
positive and negative patient samples or a positive and a negative quality control sample 
to validate the testing process and the new instrument. Once validation is successful, the 




implementation plan. Making sure that infrastructures, including electricity, water, 
consumables, training of all laboratory technicians, including all trouble-shooting 
training, are completed before starting the TB testing. It is a widespread problem that 
instruments remain inoperative for an extended period waiting for a technical assistant 
from medical device companies that are not always nearby (Umubyeyi et al., 2016).  
For failed laboratory steps, the study recommends clear documentation of why a 
laboratory process failed. The research also suggests that the laboratory should document 
what steps were taken to correct any failure of the laboratory process. Clinical 
laboratories play a significant role in identifying and treatment of a specific disease. 
However, throughout this research study, it is cited that the infrastructure, level of 
support for surveillance, research, and training in health care fields in Ethiopia is 
minimal. However, based on this study’s results, it is suggested that the laboratory 
professionals who are managing the TB laboratory or those who are overseeing the 
laboratory procedures need to be fully engaged to make sure that TB laboratory tests are 
performed and obtain a valid test result. WHO allows 5-15% error or invalid results. The 
study recommends that the ZN microscopic test with no results, error/invalid test result 
and less than three sputum samples should have: 
• Documentation to explain why the test failed  
• Documentation for corrective action. One example of a corrective action could be 
repeating the test and releasing the test result the same day. 
• Documentation of reason for less than three sputum samples collection and a 




I also recommend future studies to analyze the reason for the failure of a process (error, 
invalid, undocumented, not collected) as part of the study.  
Implications for Professional Practice and Social Change 
The study captures the day to day activities of a community health TB laboratory 
revealing the success, and the challenges faced when implementing the use of high-tech 
instruments like the Gene Xpert MDR RIF-R PCR Assay. It is vital to evaluate resources 
in terms of infrastructure, technical, and material resources before implementing a highly 
specialized process that requires immediate attention and support. Assessing, 
understanding, and evaluating existing laboratory procedures is only a start. The study 
result will be disseminated including to FDREMOH. 
The answer to Ethiopia’s TB disease complexity should come from Ethiopians 
leadership of scientific research. This can only happen with full engagement of 
laboratorians and researchers in understanding the local laboratory concerns and other 
related problems, no matter how small and redressing it from their point of view, 
ensuring the sustainability of resources needed. Zumla et al. (2015) ascertained that the 
more African scientists and researchers take on the leadership role, it has become 
imperative that other funding agencies consider aligning their research and capacity 
building investments in Africa to have a cooperative and growing effect. It is only 
through the empowerment of the next generation of African scientific leaders who will 
conduct the highest level of research that Africa will be able to generate local solutions to 




 Umubyeyi et al. (2016) stated that Implementation of Xpert MTB/RIF, new 
technology, requires better country preparedness. Training, policies, and plans to address 
operational issues, comprehensive technical assistance, significant laboratory 
infrastructure improvement, and finally, the development of a TB laboratory strategic 
plan from the local government official and laboratory managers. It should include a 
proposal to the roll-out of Xpert Gene Xpert MDR RIF-R PCR Assay and coordinate 
support from donors and partners. 
  Umubyeyi et al. (2016) continue to discuss that countries with low resources 
have suffered from a lack of comprehensive technical assistance, including the 
formulation of policies and plans to address operational issues. 
In Ethiopia, to fulfil these requirements, countries must coordinate the support of 
donors and partners and propose a budget and plan that covers technical assistance needs, 
the development of a TB laboratory strategic plan, including the roll-out of Xpert and the 
coordination of support from donors and partners. 
I will analyze and share the outcome of the study to recommend an adjustment to 
the current processes and procedures to build on what is already achieved to move 
forward and empower local decision-makers to work towards sustained laboratory 
excellence based on available resources. Therefore, the potential impact of this study will 
reflect a positive social change at the individual, organizational, and government levels. 
Conclusion 
The study will contribute to changing the way Ethiopian laboratory technicians 




much reliance on outside prompting, which will constitute a positive social change. TB 
laboratory processes that are structured, systematized, and entirely led by local laboratory 
managers and directors, supported by government officials and international agencies, 
will have a sustained impact. Empowering local professionals and laboratory managers to 
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